A carregar...
Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
Alemtuzumab is the newest disease-modifying therapy approved for the treatment of relapsing multiple sclerosis. Alemtuzumab is an anti-CD52 targeted antibody that causes lysis of T and B lymphocytes, monocytes, natural killer cells, macrophages, and dendritic cells. Following its administration, a p...
Na minha lista:
| Publicado no: | Neuropsychiatr Dis Treat |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4445870/ https://ncbi.nlm.nih.gov/pubmed/26056453 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S60518 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|